28 January 2025
Dr Christophe Ginestier receives a €200,000 Pink Ribbon Award for his project on breast cancer treatment resistance, aimed at identifying new therapies to prevent recurrence.
news from the crcm
28 January 2025
Published in Cellular and Molecular Gastroenterology and Hepatology, the De Sepulveda team's study demonstrates that the MAN2A1-FER oncoprotein, present in several cancers, lacks kinase activity, calling into question the efficacy of tyrosine kinase inhibitors as a therapeutic strategy.
28 January 2025
The new ANR-funded project will explore the non-canonical roles of CDK6 and pave the way for innovative leukemia treatments using advanced models and drug repositioning strategies.
28 January 2025
Published in ACS Nano, the study deciphers the impact of biophysical parameters and individual immune response on the efficacy of immune cell engagers, paving the way for optimizing their design in immunotherapy.
28 January 2025
The ATI team celebrates a double victory with prestigious funding for its innovative immunotherapy projects.
28 January 2025
The Predictive Oncology team is proud to once again receive the support of the Ligue Contre le Cancer.
28 January 2025
During the event, Dr. Emilie Mamessier presented the team and its work in progress to all CRCM members, highlighting the innovative research being carried out in the fight against cancer.
28 January 2025
The Borg / Maina "Targeting signaling networks and the microenvironment in cancer" team kicks off 2025 by welcoming three Master 2 students. Saliha, Jules and Camille join our ranks!
28 January 2025
Our team recently invested in a D300e digital distributor from TECAN. This acquisition opens up new prospects for high-throughput trials and the identification of innovative treatments.
28 January 2025
Members of the Oncologie Prédictive team mobilized for "La Marseillaise des Femmes".
28 January 2025
The Predictive Oncology team was on hand to support the fight against breast cancer.
14 January 2025
Published by Poplineau et al. in 2022, the article "Noncanonical EZH2 drives retinoic acid resistance in AML by repressing retinoic acid targets" made the cover of the issue.